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Long-term eﬀ ectiveness and cost-eﬀ ectiveness of cognitive 
behavioural therapy as an adjunct to pharmacotherapy for 
treatment-resistant depression in primary care: follow-up of 
the CoBalT randomised controlled trial
Nicola J Wiles, Laura Thomas, Nicholas Turner, Kirsty Garﬁ eld, Daphne Kounali, John Campbell, David Kessler, Willem Kuyken, Glyn Lewis, 
Jill Morrison, Chris Williams, Tim J Peters, Sandra Hollinghurst
Summary
Background Cognitive behavioural therapy (CBT) is an eﬀ ective treatment for people whose depression has not 
responded to antidepressants. However, the long-term outcome is unknown. In a long-term follow-up of the CoBalT 
trial, we examined the clinical and cost-eﬀ ectiveness of cognitive behavioural therapy as an adjunct to usual care that 
included medication over 3–5 years in primary care patients with treatment-resistant depression.
Methods CoBalT was a randomised controlled trial done across 73 general practices in three UK centres. CoBalT 
recruited patients aged 18–75 years who had adhered to antidepressants for at least 6 weeks and had substantial 
depressive symptoms (Beck Depression Inventory [BDI-II] score ≥14 and met ICD-10 depression criteria ). Participants 
were randomly assigned using a computer generated code, to receive either usual care or CBT in addition to usual 
care. Patients eligible for the long-term follow-up were those who had not withdrawn by the 12 month follow-up and 
had given their consent to being re-contacted. Those willing to participate were asked to return the postal questionnaire 
to the research team. One postal reminder was sent and non-responders were contacted by telephone to complete a 
brief questionnaire. Data were also collected from general practitioner notes. Follow-up took place at a variable 
interval after randomisation (3–5 years). The primary outcome was self-report of depressive symptoms assessed by 
BDI-II score (range 0–63), analysed by intention to treat. Cost-utility analysis compared health and social care costs 
with quality-adjusted life-years (QALYs). This study is registered with isrctn.com, number ISRCTN38231611.
Findings Between Nov 4, 2008, and Sept 30, 2010, 469 eligible participants were randomised into the CoBalT study. Of 
these, 248 individuals completed a long-term follow-up questionnaire and provided data for the primary outcome (136 in 
the intervention group vs 112 in the usual care group). At follow-up (median 45·5 months [IQR 42·5–51·1]), the 
intervention group had a mean BDI-II score of 19·2 (SD 13·8) compared with a mean BDI-II score of 23·4 (SD 13·2) for 
the usual care group (repeated measures analysis over the 46 months: diﬀ erence in means –4·7 [95% CI –6·4 to –3·0, 
p<0·001]). Follow-up was, on average, 40 months after therapy ended. The average annual cost of trial CBT per participant 
was £343 (SD 129). The incremental cost-eﬀ ectiveness ratio was £5374 per QALY gain. This represented a 92% probability 
of being cost eﬀ ective at the National Institute for Health and Care Excellence QALY threshold of £20 000.
Interpretation CBT as an adjunct to usual care that includes antidepressants is clinically eﬀ ective and cost eﬀ ective 
over the long-term for individuals whose depression has not responded to pharmacotherapy. In view of this robust 
evidence of long-term eﬀ ectiveness and the fact that the intervention represented good value-for-money, clinicians 
should discuss referral for CBT with all those for whom antidepressants are not eﬀ ective.
Funding National Institute for Health Research Health Technology Assessment.
Copyright © Wiles et al. Open Access article distributed under the terms of CC BY.
Introduction
Cognitive behavioural therapy (CBT) is an eﬀ ective 
treatment for depression,1,2 including for those who 
have not responded to antidepressants.3 CBT teaches 
patients skills to help them better manage their mood, 
and so has the potential to result in beneﬁ t that is 
sustained beyond the end of therapy. However, little 
evidence of long-term eﬀ ectiveness exists. Many trials 
report outcomes at the end of therapy2 and although 
there is evidence that CBT is eﬀ ective3–8 and cost 
eﬀ ective9,10 in the medium term (6–12 months), many of 
these trials are small with sample sizes of fewer than 
75 participants per group.4–7 Trials of CBT in relapse 
prevention (with sample sizes of 40 followed up at 4 and 
6 years11,12 and 158 participants followed up at roughly 
6 years13) suggest that CBT might be eﬀ ective in the 
long-term. A 6-year follow-up of patients with residual 
depressive symptoms (not major depression) randomly 
assigned to CBT or usual care,14 found that the diﬀ erence 
in recurrence between groups persisted for 3 years.13 
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Data for long-term cost-eﬀ ectiveness are sparse, yet the 
cost to health services and society is well recognised.15,16 
Resource use data were not collected in the long-term 
follow-ups of CBT for relapse prevention.11–13 Other 
reports about the cost-eﬀ ectiveness of CBT relate to 
diﬀ erent patient populations and briefer interventions.17 
In view of the chronic relapsing nature of depression, 
knowledge of long-term outcomes and cost-eﬀ ectiveness 
is needed.1
Despite expansions in psychological services in the 
UK18 and elsewhere, CBT is still a limited resource, often 
reserved for those with treatment-resistant depression 
who have not responded to antidepressants. The latter 
group represent a high proportion (>50%) of those treated 
with medication in primary care.19 To inform decision 
making, evidence should be obtained to substantiate and 
quantify the potential for long-term beneﬁ t in this group.
We report the long-term follow-up of the CoBalT trial. 
We aimed to examine whether CBT (in addition to usual 
care that included pharmacotherapy) was eﬀ ective and 
cost eﬀ ective in reducing depressive symptoms and 
improving quality of life over the long-term (3–5 years)
compared with usual care alone in primary care patients 
with treatment-resistant depression.
Methods
Study design and participants
The design of the CoBalT trial has been previously 
described.3 The CoBalT trial was a multicentre randomised 
controlled trial done across 73 general practices in three 
UK centres.3,10,20  CoBalT recruited patients aged 18–75 years 
who had adhered to antidepressants for at least 6 weeks 
and had substantial depressive symptoms (Beck 
Depression Inventory21 [BDI-II] score ≥14 and met the 
ICD-10 depression criteria).3 This deﬁ nition of treatment-
resistant depression was inclusive and directly relevant to 
primary care. 
Participants were randomly assigned to continue with 
usual care from their general practitioner, or to receive 
12–18 sessions of CBT in addition to usual care.
Randomisation was by means of a computer-generated 
code from a remote automated telephone randomisation 
service. Allocation was stratiﬁ ed by centre and minimised 
according to four factors (baseline BDI-II score, whether 
the general practice had a counsellor, previous treatment 
with antidepressants, and duration of depression at 
baseline). Therapists were representative of those 
working in NHS psychology services.3 An independent 
assessor conﬁ rmed that therapy was delivered 
competently.22 Participants and investigators were not 
masked to treatment assignment because of the nature 
of the intervention.
Patients eligible for long-term follow-up were those 
who had not withdrawn during the 12 month follow-up 
and had consented to be contacted about future research. 
Ethical approval for the follow-up study was given by the 
National Research Ethics Service Committee West 
Midlands, Edgbaston (reference number 13/WM/0149). 
Research governance approvals were obtained from the 
relevant local Research Ethics Committees and Clinical 
Commissioning Groups or Health Boards covering the 
three study sites (Bristol, Exeter, and Glasgow). The 
protocol is available online.  
Procedures
General practices excluded individuals who had died, 
and those it was inappropriate to re-contact (eg, people 
who were terminally ill) from the list of potential 
participants. Participants were mailed an invitation letter, 
information leaﬂ et, and questionnaire to collect data for 
the various outcomes. Those willing to participate were 
asked to return the completed questionnaire to the 
research team. One postal reminder was sent and 
non-responders contacted by telephone to complete a 
Research in context
Evidence before this study
Recent systematic reviews of interventions for patients with 
treatment resistant depression have underlined the paucity of 
high quality evidence in this area. In a review focused on 
psychological interventions, there were only ﬁ ve included 
studies of cognitive behavioural therapy (CBT; including our 
pilot study for CoBalT) and most trials were small (with sample 
sizes of less than 100 participants per group) or had outcomes 
at 8–20 weeks, or both, emphasing the lack of robust evidence 
of long-term eﬀ ectiveness. Subsequent to the period covered 
by these reviews, we published the ﬁ ndings from the 
multicentre CoBalT trial, which had a sample size of 
469 participants. We found that CBT when given as an adjunct 
to usual care that included antidepressants was a clinically and 
cost-eﬀ ective treatment for primary care patients whose 
depression had not responded to treatment with medication. 
However, the follow-up for CoBalT was limited to 12 months 
and hence no evidence exists with regards to long-term 
outcomes. In view of the chronic relapsing nature of depression, 
it is important to substantiate and quantify the potential for 
long-term gain.
Added value of this study
To our knowledge, this study has provided the ﬁ rst evidence of 
the long-term eﬀ ectiveness (3-5 years) and cost-eﬀ ectiveness 
of CBT as an adjunct to pharmacotherapy for primary care 
patients with treatment-resistant depression.
Implications of all the available evidence
In view of this robust evidence of long-term eﬀ ectiveness and 
the fact that the intervention represented good value for 
money, clinicians should discuss referral for CBT with all those 
for whom antidepressants are not eﬀ ective. 
For expansions in psychological 
services elsewhere see 
http://www.health.gov.au/
mentalhealth-betteraccess
For protocol see 
http://www.bristol.ac.uk/
psychiatry/research/resources
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brief questionnaire, which included the Patient Health 
Questionnaire 9 (PHQ-9), questions about use of, and 
adherence to, antidepressants, and questions about use 
of health-care services. Follow-up took place at a variable 
interval after randomisation (3–5 years). Individuals who 
had moved were traced through the Health and Social 
Care Information Centre. Consent for tracing was 
obtained previously.
Outcomes
The primary outcome was self-report of depressive 
symptoms assessed by BDI-II score21 (range 0–63). 
Secondary outcomes were response (≥50% reduction in 
depressive symptoms relative to baseline); remission 
(BDI-II score <10); quality of life (Short-Form health survey 
12 [SF-12]);23 and measures of depression (PHQ-9)24 and 
anxiety (Generalised Anxiety Disorder assessment 7 
[GAD-7])25 used in psychological services. Data for the use 
of, and adherence to, antidepressants were collected and 
current comorbidities were ascertained. Data for health 
care used in primary and secondary care and 
complementary and alternative therapy were collected for 
the economic evaluation. Participants also completed the 
EQ-5D-5L (a standardised generic measure of health status 
used as part of the economic evaluation).26 In a random 
sample of 50 participants from Bristol practices, data for 
primary care consultations and antidepressant medication 
since the 12 month follow-up were obtained to inform the 
economic evaluation.
Statistical analysis
A predeﬁ ned analysis plan was agreed with the Trial 
Steering Committee. The primary outcome for the main 
trial was a binary response variable; for this follow-up, the 
primary outcome was speciﬁ ed as a continuous outcome 
(BDI-II score) to maximise power. The change in the 
speciﬁ cation of the primary outcome for the long-term 
follow-up was made at the time the request for additional 
funding was submitted to the funder (Nov 6, 2012).
Repeated measures analyses compared the groups as 
randomised by intention to treat, incorporating outcomes 
at 6 months, 12 months, and 3–5 years, adjusting for the 
original stratiﬁ cation and minimisation variables (study 
centre, baseline BDI-II score, whether the practice had a 
counsellor, previous treatment with antidepressants, and 
duration of their depressive episode at baseline) and 
baseline measurement of the outcome. These analyses 
used an extension to generalised estimating equations 
(Stata: xtqls command) using a Markov correlation 
structure to allow for the unequal spacing of measurements 
over time.27 The summary eﬀ ect measure represented the 
average diﬀ erence in mean BDI-II scores between 
treatment groups over time. We formally assessed whether 
the treatment eﬀ ects reported over 12 months were 
sustained or declined over the long term by introducing an 
interaction between time (in months since randomisation 
included as linear covariate) and treatment allocation in 
the model. Similar regression models were used for 
analysis of the secondary outcomes. Diﬀ erences in means, 
odds ratios, 95% CIs, and p values are reported.
Sensitivity analyses examined the eﬀ ect of missing data 
using the multiple imputation by chained equation 
approach,28 and linear random eﬀ ect models,29 modelling 
outcome trajectories jointly with the wave-speciﬁ c 
probabilities of loss to follow-up.30,31 We compared two 
alternative models for modelling loss to follow-up: 
(1) a model where loss to follow-up at each wave depended 
on the previous level of the patient’s outcome (missing at 
random); and (2) where loss to follow-up depended on 
the current value of the outcome (informative drop-out 
or missing not at random; appendix, p 4). 
The economic evaluation was done from the perspective 
of UK NHS and personal social services. We obtained 
information about patients’ health care resource use for 
the past 6 months from the questionnaire. To estimate 
resource use during the whole follow-up period, we 
combined questionnaire data with resource use data from 
the main trial at an individual level and extrapolated. 
Estimates were reﬁ ned using data for consultations and 
antidepressant medication collected for 50 patients for the 
whole period from general practitioner records. Resource 
use was valued at 2013 prices, using relevant unit costs 
(appendix p 2)32–34 or inﬂ ated using the hospital and 
community health services index.32 Costs and quality-
adjusted life-years (QALYs) were discounted at 3·5%.35
EQ-5D-3L values collected during the trial were 
combined26 with EQ-5D-5L values at long-term follow-up 
to estimate QALYs for the whole period. We adjusted for 
baseline EQ-5D scores to account for the diﬀ erence in 
See Online for appendix
For the questions asked to 
collect data see http://www.gp-
patient.co.uk
469 enrolled and randomly assigned in CoBalT
234 assigned to cognitive 
 behavioural therapy
 and usual care
235 assigned to usual care
198 followed up at 12 months
 17 withdrew from study
 17 lost to follow-up
 2 died
198 followed up at 12 months
 15 withdrew from study
 22 lost to follow-up
126 followed up at 46 months
  2 died
  7 excluded by general 
 practitioner
  15 withdrew by 12 months
 3 no consent to re-contact
  11 could not be traced
  20 declined contact
  51 no response
112 completed BDI-II
126 completed PHQ-9
149 followed up at 46 months
  3 died
  3 excluded by general 
   practitioner
  17 withdrew by 12 months
 2 no consent to re-contact
  10 could not be traced
  7 declined contact
  43 no response
136 completed BDI-II
148 completed PHQ-9
 Figure 1: CoBalT trial proﬁ le extended to include long-term follow-up
BDI-II=Beck Depression Inventory score. PHQ-9=Patient Health Questionnaire 9.
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scores between groups at baseline. As the follow-up 
period varied between 3 and 5 years, average annual 
values of costs and QALYS were derived to ensure 
comparability. An incremental cost-eﬀ ectiveness ratio 
was estimated and uncertainty captured with non-para-
metric bootstrapping. A cost-eﬀ ectiveness acceptability 
curve was plotted to indicate the probability of the 
intervention being cost eﬀ ective at diﬀ erent values of 
willingness to pay. Net monetary beneﬁ t statistics were 
estimated for the thresholds of £20 000 and £30 000 per 
QALY. Additional sensitivity analyses were done to test 
the robustness of our assumptions in terms of grade of 
therapist, often band 7 in Improving Access to 
Psychological Therapies services instead of 8a as in the 
trial, without using general practice note data to adjust 
resource use, and imputing missing values. Statistical 
analyses were done with Stata version 13.1. This trial is 
registered with isrctn.com, number ISRCTN38231611.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
469 participants were randomly assigned in CoBalT, 
32 withdrew from the study by 12 months, two individuals 
died, and ﬁ ve did not consent to future contact.3 Thus, 
430 individuals were eligible to participate in the long-
term follow-up. Of these, a further three individuals died 
between the 12 month and 46 month follow-up (one in 
the intervention group and two in the usual care group), 
ten were excluded by their general practitioner, and 
21 could not be traced. Hence, 396 individuals were 
invited to participate between Sept 1, 2013, and April 14, 
2014, in which time 275 individuals had completed a 
questionnaire. 27 individuals declined to participate and 
94 did not respond. Long-term follow-up data were 
available for 59% of the original 469 partici pants randomly 
assigned. The median time from rando misation to long-
term follow-up questionnaire completion was 
45·5 months (IQR 42·5–51·1), which was, on average, 
39·7 months (SD 5·2) after the end of therapy for those 
who had had at least 12 sessions of CBT (n=105). 149 
(64%) participants were followed up in the intervention 
group compared with 126 (54%) in the usual care group 
(ﬁ gure 1). Of these, 136 participants in the intervention 
group and 112 participants in the usual care group 
completed the BDI-II questionnaire and 148 participants 
in the intervention group and 126 participants in the 
usual care group completed the PHQ-9 questionnaire.
At trial entry, most participants had severe (mean 
baseline BDI-II score 30·9 [SD 9·8]) and chronic 
depression (duration ≥2 years, n=162 [59%]).3 66 parti-
cipants (24%) met ICD-10 criteria for severe depression.3 
Physical and psychological comorbidity were common.3 
205 (75%) had a secondary diagnosis of an anxiety disorder. 
At the long-term follow-up, 199 (80%) participants reported 
at least one long-term health condition (of 249 participants 
who completed the full-length questionnaire). 115 reported 
musculoskeletal problems, 53 reported high blood 
pressure, 48 reported asthma or chest problems, and 
34 reported diabetes.
Participants in the intervention group had a BDI-II 
score that was, on average, 3·6 points lower (less 
depressed, 95% CI –6·6 to –0·6) at 46 months than those 
Intervention Usual care Adjusted diﬀ erence in means 
at 46 months or adjusted 
odds ratio* (95% CI)
Repeated measures analyses
N n (%) or mean 
(SD) at 46 
months
N n (%) or mean 
(SD) at 
46 months
N Adjusted diﬀ erence in 
means or adjusted odds 
ratio* (95% CI)
p value Eﬀ ect size for 
continuous 
outcomes
Primary outcome
BDI-II score 136 19·2 (13·8) 112 23·4 (13·2) –3·6 (–6·6 to –0·6) 1062 –4·7 (–6·4 to –3·0) <0·001 0·45
Secondary outcomes
Response 136 59 (43%) 112 30 (27%) 2·09 (1·19 to 3·67) 1062 2·65 (1·97 to 3·55) <0·001 ··
Remission (BDI-II <10) 136 38 (28%) 112 20 (18%) 1·77 (0·93 to 3·39) 1062 2·49 (1·84 to 3·38) <0·001 ··
Percentage change in BDI-II score 136 –36·4% (42·3) 112 –21·0% (42·0) –14·9% (–25·1 to –4·7) 1062 –18·2% (–23·7 to –12·6) <0·001 ··
PHQ-9 148 9·5 (7·1) 126 11·1 (6·3) –1·6 (–3·0 to –0·1) 1470 –2·4 (–3·1 to –1·6) <0·001 0·42
GAD-7 136 7·1 (5·9) 113 8·4 (5·5) –1·1 (–2·4 to 0·2) 1064 –1·9 (–2·6 to –1·2) <0·001 0·37
SF-12 mental subscale 132 38·7 (12·1) 110 34·6 (11·8) 3·5 (0·7 to 6·3) 1041 4·5 (2·8 to 6·2) <0·001 0·49
SF-12 physical subscale 132 42·2 (13·8) 110 39·2 (13·5) 0·9 (–2·0 to 3·7) 1041 –0·3 (–1·6 to 1·0) 0·672 0·02
BDI-II=Beck Depression Inventory score. PHQ-9=Patient Health Questionnaire 9. GAD-7= Generalised Anxiety Disorder assessment 7. SF-12=Short-Form health survey 12. *The intention-to-treat analysis adjusted for 
baseline measure of outcome and the stratiﬁ cation (centre) and minimisation variables (baseline BDI-II score, previously prescribed antidepressants, whether the general practice had a counsellor, and duration of 
current episode of depression at baseline). 
Table 1: Intention-to-treat analyses of primary and secondary outcomes over 46 months
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in the usual care group (table 1). In repeated measures 
analyses, using data from 6, 12, and 46 months (ﬁ gure 2, 
appendix, p 3), individuals in the intervention group had 
a mean BDI-II score that was, on average, 4·7 points 
lower (–6·4 to –3·0) over the 46 months compared with 
those in the usual care group (table 1). This equated to an 
eﬀ ect size of 0·45 using the baseline SD for BDI-II 
(pooled). Mean BDI-II scores at 46 months for the usual 
care group were similar to scores at 6 and 12 months 
(ﬁ gure 2, appendix, p 3).3 Although the intervention 
eﬀ ect decreased slightly across the timepoints, there was 
no statistical evidence of an interaction between 
treatment allocation and time (p=0·29).
A beneﬁ cial eﬀ ect of the intervention was found for all 
secondary outcomes except the SF-12 physical health 
subscale (table 1). Individuals in the intervention group 
had nearly a three-fold increased odds of response over 
the 46 months compared with those in the usual care 
group. Those in the intervention group were also more 
likely to experience remission (BDI-II score <10), 
a reduction in anxiety (GAD-7), and greater improvement 
on the SF-12 mental health subscale over the 46 months 
compared with those in the usual care group (table 1). 
There was no statistical evidence that the eﬀ ect of the 
intervention varied over time (interactions between 
treatment allocation and time: p>0·11). Inclusion of a 
quadratic term for time made no diﬀ erence to the 
ﬁ ndings. The results of sensitivity analyses to examine 
the robustness of the ﬁ ndings to varying assumptions 
about missing data identiﬁ ed either slightly smaller or 
larger eﬀ ects, albeit consistent with the results using all 
available data (appendix, p 5).
197 (72%) participants reported taking antidepressants 
for the time since the 12 month follow-up, but sustained 
use of antidepressants was lower in the intervention 
group than in the usual care group (101 [68%] in the 
intervention group vs 96 [76%] in the usual care group). 
The intervention group were less likely to be taking 
antidepressants at 46 months (120 in the intervention 
group [81%] vs 107 [85%] in the usual care group; 
diﬀ erence –4·4% [95% CI –13·3 to 4·5]), but the 
percentage who adhered to their medication was slightly 
higher in the intervention group (111 [93%] of 120) 
compared with the usual care group (96 [90%] of 107); 
diﬀ erence 2·8% [–4·7 to 10·2]). However, the 95% 
surrounding these diﬀ erences included the null. Only 
ﬁ ve participants had used a computerised or internet-
based CBT package since the 12 month follow-up 
(appendix, p 9). 34 (27%) participants in the usual care 
group and 31 (21%) in the intervention group had 
received counselling or talking therapy since the 
12 month follow-up (appendix, p 9). However, only 
17 individuals had received cognitive therapy, and only 
ﬁ ve had received 12 sessions.
The economic evaluation using complete-case data 
included 116 (50%) of 234 participants in the intervention 
group and 98 (42%) of 235 participants in the usual care 
group. Average annual NHS and personal social service 
resource use was similar between the two groups 
(appendix, p 10), emulating the 1 year follow-up result.10 
The results from the base case cost-utility analysis are 
presented in table 2. The mean annual cost per 
participant of the intervention was £343. NHS and 
personal social service costs were slightly higher in the 
usual care group (£604 vs £542), resulting in an annual 
incremental cost of £281 (95% CI £32–£531). Mean 
annualised QALYs were higher in the intervention group 
(0·596 vs 0·544), representing better health-related 
quality of life over the whole period. The incremental 
cost-eﬀ ectiveness ratio was £5374. At a societal 
willingness to pay of £20 000 per QALY, the net monetary 
beneﬁ t per patient per year was £782, with a probability 
of 0·92 of being cost eﬀ ective (ﬁ gure 3). Results remained 
robust throughout sensitivity analyses (appendix, p 11). If 
therapists were employed at grade 7, the incremental 
Figure 2: Mean BDI-II scores for the intervention and usual care groups at 6, 
12, and 46 months
Error bars represent SD. BDI-II=Beck Depression Inventory score.
Intervention (n=116) Usual care (n=98)
All primary care £412 (570) £472 (809)
Antidepressants £64 (97) £87 (168)
Hospital care £50 (294) £37 (186)
Personal social services £17 (112) £9 (49)
National health service and personal social services total £542 (912) £604 (904·15)
Cost of cognitive behavioural therapy £343 (129) ··
Total cost £885 (937·92) £604 (904·15)
QALYs 0·596 (0·17) 0·544 (0·20)
Incremental cost (95% CI) £281 (32–531) ··
Incremental beneﬁ t, QALY gain (95% CI) 0·052 (0·003–0·102) ··
Incremental cost-eﬀ ectiveness ratio, cost per QALY gain £5374 ··
Median net monetary beneﬁ t (probability net monetary 
beneﬁ t>0)
·· ··
Willingness to pay=£20 000 per QALY 782 (0·92) ··
Willingness to pay=£30 000 per QALY 1317 (0·95) ··
Data are mean (SD), unless otherwise speciﬁ ed. Mean annual cost and beneﬁ t per participant are only presented for 
complete cases. QALY=Quality-adjusted life-year.
Table 2: Cost-utility analysis from a National Health Service and personal social services perspective
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cost-eﬀ ectiveness ratio decreased to £4622. Without 
using general practitioner note data to adjust resource 
use, the incremental cost-eﬀ ectiveness ratio increased 
slightly to £5982. With all missing data imputed, the 
incremental cost-eﬀ ectiveness ratio increased to £6890. 
The probability of the intervention being cost eﬀ ective 
ranged from 0·92 to 0·94 at a societal willingness to pay 
of £20 000 per QALY (appendix, p 11).
Discussion
CBT as an adjunct to usual care was an eﬀ ective 
treatment for primary care patients with treatment-
resistant depression over the long-term, and represented 
good value for money. The intervention reduced 
depressive symptoms and improved quality of life over 
an average of 46 months. This was, on average, 
40 months after the end of therapy. A long-term beneﬁ t 
was also seen in terms of remission of symptoms. In 
view of the fact that, at baseline, most CoBalT 
participants had severe and chronic depression, with 
physical or psychological comorbidity, or both, these 
results are noteworthy and have clear implications for 
clinical practice.
To our knowledge, this study is the ﬁ rst to show long-
term eﬀ ectiveness of CBT as an adjunct to pharma co-
therapy for primary care patients with treat ment-resistant 
depression. Previous systematic reviews36,37 underlined the 
absence of high quality evidence in this area. Earlier trials 
were small (with sample sizes of less than 100 participants 
per group) with only short-term outcomes (8–20 weeks).36 
Previous ﬁ ndings from the CoBalT trial were the ﬁ rst 
evidence of sustained eﬀ ectiveness at 12 months.3 Other 
studies reporting outcomes 6–12 months after the end of 
CBT are small (with sample sizes of less than 
75 participants per group),4–7 with one exception,8 and 
long-term outcome data (4–6 years) relate to CBT for 
relapse prevention.11–13 Other psychological therapies 
might be as eﬀ ective as CBT in the short-to-medium 
term,38 but no evidence of long-term eﬀ ectiveness exists.
The health-care costs of individuals with treatment-
resistant depression are larger than for many other 
groups.39,40 However, we previously showed that CBT was 
a cost-eﬀ ective treatment for patients with treatment-
resistant depression over a 12 month period.10 Present 
ﬁ ndings represent the ﬁ rst evidence of long-term cost-
eﬀ ectiveness. The cost diﬀ erence between groups was 
driven by the initial cost of therapy, as health-care costs 
were very similar for the duration and no top-up sessions 
were oﬀ ered. The beneﬁ t, in terms of health-related 
quality of life, was sustained over time, and therefore 
achieved at no additional cost. This ﬁ nding reinforces our 
conclusion at 12 months that investing in CBT services 
for these patients represents an eﬃ  cient use of health-
care resources. Although lost productivity was not 
investigated in the long-term follow-up and a diﬀ erence 
between groups was not evident at 12 months,10 the 
sustained eﬀ ect might aﬀ ect paid and non-paid activities 
as well as wider societal beneﬁ ts, such as the wellbeing of 
families.
Our study had several strengths and limitations. The 
sample size of this study was large and it was set in UK 
primary care. Although participants in the intervention 
group were more likely to be followed up at 46 months, 
in sensitivity analyses, no evidence existed that missing 
data had biased the ﬁ ndings for either the clinical or the 
cost-eﬀ ectiveness analyses. In terms of costs, for the 
various sensitivity analyses, the estimated incremental 
cost-eﬀ ectiveness ratio remained well below the £20 000 
per QALY threshold used by the National Institute for 
Health and Care Excellence. 
Limited resources meant that the long-term follow-up 
data were collected by postal questionnaire rather than 
self-completion of a questionnaire at a face-to-face 
appointment with a researcher (as at the 6 and 12 month 
follow-ups). This diﬀ erence probably aﬀ ected the 
response rate achieved, although as stated above, there 
was no evidence of bias because of missing data. 
Importantly, collection of the same outcome measures 
as the original trial enabled comparison of data in the 
long-term. Only a small number of patients received 
CBT after the end of the trial (12 months); therefore, 
contamination did not aﬀ ect the ﬁ ndings. The proportion 
taking long-term anti depressants was also similar 
between groups. We aimed to reduce patient reporting 
bias by validating self-report data with patient notes, 
which resulted in slightly higher estimates of NHS and 
personal social services costs, implying patients had 
under-reported their health-care use. However, the 
diﬀ erence was small, as shown by sensitivity analyses, 
and there was no apparent diﬀ erence between the two 
groups, allowing us to be conﬁ dent in our estimations of 
resource use for the whole period.
More than 50% of primary care patients with 
depression do not respond to antidepressants.19 Our 
ﬁ ndings provide robust evidence for the eﬀ ectiveness of 
CBT given as an adjunct to usual care that includes 
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Figure 3: Cost-eﬀ ectiveness acceptability curve showing the probability that 
the intervention is cost eﬀ ective at diﬀ erent levels of willingness to pay
QALY=quality-adjusted life-year.
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medication in reducing depressive symptoms and 
improving quality of life over the long term. The eﬀ ects 
observed were substantial and represented good value 
for money. As most of the CoBalT participants had severe 
and chronic depression, with physical or psychological 
comorbidity, or both, these results should oﬀ er hope for 
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need to discuss referral for CBT with all those for whom 
antidepressants are not eﬀ ective.
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beneﬁ ts. Only by doing so will we be able to improve 
outcomes for a condition that leads to substantial 
disability in developed countries.
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